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Abstract: Influenza A virus causes annual epidemics and
occasional pandemics of short-term respiratory infections
associated with considerable morbidity and mortality. The
pandemics occur when new human-transmissible viruses
that have the major surface protein of influenza A viruses
from other host species are introduced into the human
population. Between such rare events, the evolution of
influenza is shaped by antigenic drift: the accumulation of
mutations that result in changes in exposed regions of the
viral surface proteins. Antigenic drift makes the virus less
susceptible to immediate neutralization by the immune
system in individuals who have had a previous influenza
infection or vaccination. A biannual reevaluation of the
vaccine composition is essential to maintain its effective-
ness due to this immune escape. The study of influenza
genomes is key to this endeavor, increasing our under-
standing of antigenic drift and enhancing the accuracy of
vaccine strain selection. Recent large-scale genome
sequencing and antigenic typing has considerably im-
proved our understanding of influenza evolution: epi-
demics around the globe are seeded from a reservoir in
East-Southeast Asia with year-round prevalence of influ-
enza viruses; antigenically similar strains predominate in
epidemics worldwide for several years before being
replaced by a new antigenic cluster of strains. Future in-
depth studies of the influenza reservoir, along with large-
scale data mining of genomic resources and the
integration of epidemiological, genomic, and antigenic
data, should enhance our understanding of antigenic drift
and improve the detection and control of antigenically
novel emerging strains.
Influenza is a single-stranded, negative-sense RNA virus that
causes acute respiratory illness in humans. In temperate regions,
winter influenza epidemics result in 250,000–500,000 deaths per
year; in tropical regions, the burden is similar [1,2]. Influenza
viruses of three genera or types (A, B, and C) circulate in the
human population. Influenza viruses of the types B and C evolve
slowly and circulate at low levels. Type A evolves rapidly and can
evade neutralization by antibodies in individuals who have been
previously infected with, or vaccinated against, the virus. As a
result it regularly causes large epidemics. Furthermore, distinct
reservoirs of influenza A exist in other mammals and in birds. Four
times in the last hundred years these reservoirs have provided
genetic material for novel viruses that have caused global
pandemics [3–8].
The genome of influenza A viruses comprises eight RNA
segments of 0.9–2.3 kb that together span approximately 13.5 kb
and encode 11 proteins [9]. Segment 4 encodes the major surface
glycoprotein called hemagglutinin (H), which is responsible for
attaching the virus to sialic acid residues on the host cell surface and
fusing the virus membrane envelope with the host cell membrane,
thus delivering the viral genome into the cell (Figure 1). Segment 6
encodes another surface glycoprotein called neuraminidase (N),
which cleaves terminal sialic acid residues from glycoproteins and
glycolipids on the host cell surface, thus releasing budding viral
particles from an infected cell [10]. Influenza A viruses are further
classified into distinct subtypes based on the genetic and antigenic
characteristics of these two surface glycoproteins. Sixteen hemag-
glutinin (H1–16) and nine neuraminidase subtypes (N1–9) are
known to exist, and they occur in various combinations in influenza
viruses endemic in aquatic birds [10,11]. Viruses with the subtype
composition H1N1 and H3N2 have been circulating in the human
population for several decades. Of these two subtypes, H3N2
evolves more rapidly, and has until recently caused the majority of
infections [1,12,13]. In the spring of 2009, however, a new H1N1
virus originating from swine influenza A viruses, and only distantly
related to the H1N1 already circulating, gained hold in the human
population. The emergence of this virus has initiated the first
influenza pandemic of the twenty-first century [7,14,15].
Hemagglutinin is about five times more abundant than
neuraminidase in the viral membrane and is the major target of
the host immune response [16–18]. Following exposure to the
virus, whether by infection or vaccination, the host immune system
acquires the capacity to produce neutralizing antibodies against
the viral surface glycoproteins. These antibodies participate in
clearing an infection and may protect an individual from future
infections for many decades [19]. Five exposed regions on the
surface of hemagglutinin, called epitope sites, are predominantly
recognized by such antibodies [16,17]. However, the human
subtypes of influenza A continuously evolve and acquire genetic
mutations that result in amino acid changes in the epitopes. These
changes reduce the protective effect of antibodies raised against
previously circulating viral variants. This ‘‘antigenic drift’’
necessitates frequent modification and readministration of the
influenza vaccine to ensure efficient protection (Box 1).
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Organization (WHO) maintains a global surveillance program. A
panel of experts meets twice a year to review antigenic, genetic, and
epidemiological data and decides onthe vaccine compositionforthe
next winter season in the northern or southern hemisphere [20]. If
an emerging antigenic variant is detected and judged likely to
become predominant, an update of the vaccine strain is recom-
mended. This ‘‘predict and produce’’ approach mostly results in
efficient vaccines that substantially limit the morbidity and mortality
of seasonal epidemics [21]. The recommendation has to be made
almost a year before the season in which the vaccine is used,
however, because of the time required to produce and distribute a
new vaccine. Problems arise when an emerging variant is not
identified early enough for an update of the vaccine composition
[22–24]. Thus, gaining a detailed understanding of the evolution
and epidemiology of the virus is of the utmost importance, as it may
lead to earlier identification of novel emerging variants [20].
The development of high-throughput sequencing has recently
provided large datasets of high-quality, complete genome
sequences for viral isolates collected in a relatively unbiased
manner, regardless of virulence or other unusual characteristics
[9,25]. Analyses of the genome sequence data combined with
large-scale antigenic typing [26,27] have given insights into the
pattern of global spread, the genetic diversity during seasonal
epidemics, and the dynamics of subtype evolution. Influenza data
repositories such as the NCBI Influenza Virus Resource (http://
www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html) [28] and the
Global Initiative on Sharing All Influenza Data (GISAID; http://
platform.gisaid.org/) database [29] make the genomic information
publicly available, together with epidemiological data for the
sequenced isolates. The GISAID model for data sharing requires
users to agree to collaborate with, and appropriately credit, all
data contributors. A notable success of this initiative has been the
contribution of countries, such as Indonesia and China, which
Figure 1. Schematic representation of an influenza A virion. Three proteins, hemagglutinin (HA, a trimer of three identical subunits),
neuraminidase (NA, a tetramer of four identical subunits), and the M2 transmembrane proton channel (a tetramer of four identical subunits), are
anchored in the viral membrane, which is composed of a lipid bilayer. The large, external domains of hemagglutinin and neuraminidase are the major
targets for neutralizing antibodies of the host immune response. The M1 matrix protein is located below the membrane. The genome of the influenza
A virus is composed of eight individual RNA segments (conventionally ordered by decreasing length, bottom row), which each encode one or two
proteins. Inside the virion, the eight RNA segments are packaged in a complex with nucleoprotein (NP) and the viral polymerase complex, consisting
of the PA, PB1, and PB2 proteins.
doi:10.1371/journal.ppat.1000566.g001
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domain. The WHO also supports the endeavor of rapid
publication of all available sequences for influenza viruses and
there is hope that comprehensive submission to public databases
will soon become a reality [24,30]. In the future, mining these
resources and establishing a statistical framework based on
epidemiological, antigenic, and genetic information could provide
further insights into the rules that govern the emergence and
establishment of antigenically novel variants and improve the
potential for influenza prevention and control.
Host Immune Evasion by Antigenic Drift and Shift
Influenza viruses can rapidly acquire genetic diversity because
of high replication rates in infected hosts, an error-prone RNA
polymerase (which introduces mutations during genome replica-
tion), and segment reassortment (Figure 2). Mutations that change
amino acid residues appear significantly more often than silent
mutations in the evolution of the hemagglutinin gene of human
influenza A, particularly in the protein epitopes [31–34]. This
observation indicates that selection for antigenic change of the
virus is the driving force in the evolutionary ‘‘arms race’’ between
the virus and the immunity of the human population [35].
Reassortment of the eight genome segments between two distinct
viruses present simultaneously in a host cell can result in hybrid
viruses with genome segments from two different progenitors.
Antigenic mapping allows researchers to generate a quantita-
tive, two-dimensional representation of antigenic distances be-
tween genetically divergent strains [26]. This technique has
revealed that the relationship between antigenic change and
genetic change is nonlinear for the hemagglutinin of influenza A/
H3N2. The rate of genetic change of the virus is almost constant
over time, but some mutations exert a disproportionately large
effect on the antigenic type, whereas others are ‘‘hitchhikers’’ with
no phenotypic effect. Elucidating the effects of different mutations
at individual sites on the antigenic type will improve our
understanding of the overall genotype-to-phenotype mapping for
antigenic drift. Furthermore, the antigenic drift of H3N2 is not
continuous but punctuated: antigenically homogenous clusters of
strains predominate for an average of 3 years before being
replaced by a new cluster. In accordance with the punctuated
nature of antigenic drift, periods of predominantly neutral
evolution alternate with periods of strong selection for antigenic
change [13,36]. Phylogenetic trees illustrating the evolution of the
hemagglutinin gene of H3N2 have a cactus-like shape with a
strong temporal structure in which the trunk represents the
succession of surviving viral lineages over time. Short side
branches indicate that most strains are driven to extinction and
that viral diversity at any given time is limited [31,34]. The
underlying causes of this punctuated antigenic drift and limited
viral diversity at a given point in time have been investigated in
phylodynamic modeling studies (Box 2).
Major changes in antigenicity (antigenic shift) are associated
with the introduction of novel viruses into the human population
that have a hemagglutinin segment of an influenza A virus from
another host species and can be transmitted efficiently among
humans [5]. Such viruses may arise by segment reassortment
between a human influenza A virus and an influenza A virus from
another host species. Alternatively, an entire virus from another
host species may cross into the human population. The
appearance of such viruses is rare, as it requires the viral genes
encoded by the different segments to be compatible with each
other and the virus to be capable of replication and transmission in
the human population, which is also thought to be a polygenic trait
[6,7,10,37,38]. Antigenic shift can have grave consequences
because neutralizing antibodies against the viral surface proteins
offer limited or no cross-protection across subtypes. Cross-
protection can also be very limited between viruses of the same
subtype that have evolved independently in different hosts for long
periods of time [14]. Thus, a larger part of the population is
susceptible to infection with such viruses than to infection with
endemic viruses [10,14]. Antigenic shift caused three global
pandemics in the twentieth century, the 1918 H1N1 pandemic,
the 1957 H2N2 pandemic, and 1968 H3N2 pandemic (reviewed
in [3–5,8]): The 1918 pandemic had the most devastating impact,
with an estimated 20–50 million deaths worldwide [39]. There is
some uncertainty concerning the origin of the 1918 virus due to
the lack of data from this time [6,40–43]. A recent phylogenetic
study suggests that this virus may have been generated by
reassortment of avian viruses with already circulating viruses in a
mammalian host such as human or swine [44]. The H2N2 virus
that caused the 1957 pandemic was a reassortant of five human
H1N1 segments and avian segments encoding the viral surface
proteins and the PB1 protein. Similarly, the reassortant H3N2
virus of the 1968 pandemic featured avian segments encoding
hemagglutinin and PB1. H3N2 still circulates today, together with
an H1N1 lineage introduced in 1977, which is similar to the H1N1
viruses circulating in the 1950s [4].
The first pandemic virus of the twenty-first century probably
entered the human population in January or February of 2009
[15]. Phylogenetic analyses of the viral genome determined that
the virus has a complex reassortment history with segments of
‘‘avian-like’’ Eurasian swine influenza A viruses (NA and M) that
were first observed in Eurasian swine in 1979, and of a triple
reassortant virus identified in North American swine after 1998.
The segments derived from the triple reassortant stem themselves
from human H3N2 (PB1), an avian influenza A virus (PA, PB2),
and classical North American swine influenza A viruses (HA, NP,
NS), which have a common ancestry with the 1918 H1N1 virus
[14,45]. Experiments have shown that the new H1N1 virus
replicates efficiently in mammalian model organisms such as
Box 1. Broadly Protective Vaccines
Current influenza vaccines are based on detergent-
inactivated viruses. They elicit antibodies with a narrow
range of protection that target predominantly the variable
regions of the hemagglutinin protein. Accordingly, the
seasonal influenza vaccine includes one strain with
segments of the surface proteins for each of the A/H1N1,
A/H3N2 and B viruses, and it is updated every 1–3 years to
match the predominant variants of influenza. Research
into vaccines that offer broader protection across diverse
subtypes and antigenic drift variants is ongoing [21,59–61].
This research is particularly important with respect to the
emergence of novel viruses with pandemic potential, such
as the 2009 H1N1 virus. In such an event, the time period
between the detection of the virus and the onset of a
pandemic is too short to produce a specific vaccine for
immediate vaccination of the population. Work in this area
is focused on developing vaccines that elicit antibodies
against conserved viral components, such as certain
regions of hemagglutinin, neuraminidase, and the M2
proton channel in the viral membrane [60]. Other types of
vaccines based on live attenuated viruses or plasmid DNA
expression vectors, or supplemented with adjuvants, show
promise in inducing a more broadly protective immune
response [61].
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of long-term circulation in the human population, particularly in
the event of further adaptive changes through mutation or
reassortment [46–48]. The novel H1N1 appears, so far, to cause
relatively mild human infections in comparison to other viruses
such as the highly pathogenic H5N1 avian influenza A viruses
that, since 1997, have repeatedly been transmitted to humans and
caused severe disease but so far have not been capable of sustained
transmission between humans. The emergence of a novel
pandemic virus, which may have been circulating undetected in
swine for a decade [14,45], has highlighted the need for increased
genomic surveillance of the viral populations in mammalian hosts
such as swine. These hosts could be a vessel for mammalian
adaptation of avian viruses, either by reassortment with human or
swine viruses or through adaptive changes [8], but have been
monitored less intensely than avian populations. The latest
emergence of a pandemic H1N1 virus has also underscored the
vital importance of further research into the molecular factors that
determine the host range and capacity for sustained human-to-
human transmission of influenza A viruses.
Reassortment in Subtype Evolution
Whole-genome studies have revealed that segment reassortment
between different viruses of the same subtype is an important
mechanism in the evolution of human-adapted subtypes and
generates extensive genome-wide diversity [34,36,49–51]. Periodic
selective sweeps caused by a novel antigenic drift variant rising to
predominance reduce the genomic diversity of the circulating viral
population, either genome-wide or for the hemagglutinin segment
only [12]. Reassortment results in substantial differences in the
evolutionary histories of individual segments. However, similarities
in the histories of some segments indicate that besides the antigenic
characteristics of hemagglutinin, the genomic context and compat-
ibility of certain segment combinations might be an important
contributor to viral fitness [12,51]. A case in point is the
antigenically novel ‘‘Fujian’’ strain which became predominant in
the 2003–2004 season, following a reassortment event that placed a
hemagglutinin segment from a lineage that had been circulating at
low levels for several years into a new genomic context [49]. The
importance of other segments in the adaptive evolution of the virus
is further supported by the observation that a number of other
segments, including the one encoding neuraminidase, evolve at
similar rates to the segment encoding hemagglutinin [12].
Geographic Spread
Genomic analysis has led to profound insights into the global
patterns of circulation and evolution of influenza A. Over the
course of seasonal epidemics in temperate regions, little evidence
has been found for selection for amino acid change and adaptive
evolution in the antigenic regions of the surface proteins [36].
There is, however, substantial genetic diversity due to multiple
introductions of distinct strains, wide spatial spread, and frequent
Figure 2. Generation of genetic diversity and antigenic drift in the evolution of human influenza A viruses. Blue and yellow viruses
depict two antigenically similar strains of the same subtype circulating in the human population. The genetic diversity of the circulating viral
population increases through mutation and reasssortment. Single white arrows indicate relationships between ancestral and descendant viruses.
White marks on the segments indicate neutral mutations and red marks indicate mutations that affect the antigenic regions of the surface proteins.
Incoming pairs of orange arrows indicate the generation of reassortants with segments from two different ancestral viruses. As these viruses continue
to circulate, immunity against them builds up in the host population, represented here by the narrowing of the bottleneck. In parallel, viruses with
mutations affecting the antigenic regions of the surface proteins accumulate in the viral population. At some point a novel antigenic drift variant,
indicated by a red colored virus, which is less affected by immunity in the human population, is generated. This variant is able to cause widespread
infection and founds a new cluster of antigenically similar strains.
doi:10.1371/journal.ppat.1000566.g002
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viral population circulating in one season does not directly seed the
epidemic in the following one. Instead, gene flow and viral spread
are global, with similar strains appearing in northern and southern
hemisphere epidemics across several seasons. There is a global
reservoir of viral diversity from which seasonal epidemics in
temperate regions are seeded [12,27,52]. This reservoir is located
in East-Southeast Asia, where a region-wide network of temporally
overlapping epidemics maintains infection incidence throughout
the year [27]. Novel strains appear in this region on average 6–9
months before they emerge in Oceania, Europe, and North
America and 12–18 months before they reach South America.
Challenges for the Future
A key objective for research into the antigenicdrift of influenza A is
to improve the accuracy of vaccine strain choice, in particular for
seasons preceding the establishment of novel antigenic drift variants.
More intensive surveillance and sampling, particularly in East-
Southeast Asia, could facilitate the early detection of novel emerging
drift variants and alleviate problems related to the time required for
vaccine production. A better understanding of the evolutionary and
epidemiological rules governing antigenic drift, viral fitness, the role
of the source region, and establishment of predominance would be
particularly helpful for the selection of vaccine strains when
considerable variation among antigenically novel strains is observed
and it is unclear which, if any, will become predominant. Such
insights are likely to come both from phylodynamic modeling studies
and by mining genomic resources for genome-wide properties
associated with viral fitness and predominance. Some molecular
properties of hemagglutinin with predictive value for this task have
already been identified [53–56], such as the number of changes at
sites under positive selection or in the most extensively altered
epitope, although the sites under selection might change over time
[26]. It is notable that the lack of antigenic information for sequenced
viral isolates in public repositories currentlyrestricts the direct analysis
of genetic determinants in antigenic drift [24]. If the World Health
Organization were to establish similar policies for the deposition of
antigenic information into publicdatabases as exist for sequence data,
this could create a valuable resource for research in this area. As
existing databases grow, new statistical and computational techniques
are being developed for interpretation of these large-scale, popula-
tion-level genomic datasets in combination with epidemiological and
phenotypic information [57]. Ultimately, the expert analysis of the
WHO in the detection and control of antigenically novel emerging
strains could be extensively supported by the development of a
suitable predictive framework based on statistical learning that takes
into consideration the population-level phylodynamics of antigenic
change [57,58]. Such a framework could utilize epidemiological,
genomic, and antigenic information and detailed knowledge of the
genetic and epidemiological characteristics of antigenic drift to assess
the likelihood of strains rising to predominance.
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